10 Majority of patients had CVD and were receiving SOC 6,7,a 97% were receiving glucose-lowering medications 6 Patient characteristics at baseline (N=9650) 6,7 Select history of CVD at baseline (N=9650) 6 Select history of medication use at baseline (N=9650) 6,10 a Standard care consisted of glucose-lowering and cardiovascular riskreducing therapies administered in accordance with local guidelines
S3 show the results for the outcome MACE: both GLP-1RA and SGLT-2 inhibitors were associated with a lower risk for MACE (13% and 11%, respectively) as compared with placebo, and a lower risk for MACE as compared with DPP-4 inhibitors (12% and 11%, respectively)
Then, we calculate the effect of the antagonist compared to the force elicited by retatrutide before this antagonist
For example: The Wegovy Savings Offer cuts the cost of Wegovy in half, for those who are eligible
or by reporting it directly at Report Suspected Criminal Activity (fda.gov)